Related Experiment Video
Updated: Jan 24, 2026

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
Published on: May 25, 2017
Antiseizure Treatments and Liver Injury: Expect (and Prevent) the Unexpected
Marjorie Bunch1, Shilpa Klocke2, Nicole Woodrich3
1Department of Neurology, Albany Medical College, Albany, NY, USA.
Abstract:
Drug-induced liver injury remains a major concern in the pharmacological management of epilepsy. Antiseizure medication (ASM)-related liver injury has multiple phenotypes, and in the majority of cases it is "idiosyncratic," involving hypersensitivity reactions. Awareness of drug- and patient-related risk factors can help direct treatment selection, monitoring, and ASM discontinuation, when necessary. This article examines the typical patterns of ASM-induced liver injury, from mild elevations of hepatic enzymes to life-threatening conditions. We also discuss risk factors, means for preventing liver injury in people with epilepsy treated with ASMs, and emerging biomarkers.
Insights
Antiseizure medication (ASM)-induced liver injury is a significant concern in epilepsy treatment, often presenting as idiosyncratic hypersensitivity reactions. Understanding risk factors and monitoring can help prevent severe liver damage.
Area of Science:
- Pharmacology
- Hepatology
- Neurology
Background:
- Drug-induced liver injury (DILI) is a critical issue in epilepsy management.
- Antiseizure medications (ASMs) can cause various liver injury phenotypes, frequently idiosyncratic and hypersensitivity-related.
- Identifying risk factors is crucial for selecting appropriate ASMs and monitoring patients.
Purpose of the Study:
- To review the spectrum of ASM-induced liver injury.
- To discuss risk factors, prevention strategies, and emerging biomarkers for liver injury in epilepsy patients on ASMs.
Main Methods:
- Literature review of typical patterns of ASM-induced liver injury.
- Examination of drug- and patient-related risk factors.
- Discussion of preventive measures and novel biomarkers.
Main Results:
- ASM-related liver injury ranges from mild enzyme elevations to severe, life-threatening conditions.
- Idiosyncratic reactions are common, involving hypersensitivity.
- Risk factor awareness aids in treatment selection and monitoring.
Conclusions:
- Proactive identification of risk factors and vigilant monitoring are essential for managing ASM-induced liver injury.
- Emerging biomarkers may offer future diagnostic and prognostic benefits.
- Optimizing ASM selection and management can mitigate liver injury risks in epilepsy patients.
Related Concept Videos
Expected Value
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Determination of Expected Frequency
Cancer Prevention
Some...
Expected Frequencies in Goodness-of-Fit Tests
Prevention of Further Absorption of Poison

